Know Your ABCs: Discovery, Differentiation, and Targeting of T-Bet+ B Cells
- PMID: 39844597
- PMCID: PMC11754996
- DOI: 10.1111/imr.13440
Know Your ABCs: Discovery, Differentiation, and Targeting of T-Bet+ B Cells
Abstract
Since their first description in 2008, T-bet+ B cells have emerged as a clinically important B cell subset. Now commonly known as ABCs (Age-associated B Cells), they are uniquely characterized by their expression of the transcription factor T-bet. Indeed, this singular factor defines this B cell subset. This review will describe the discovery of T-bet+ B cells, their role in bacterial infection as T cell-independent (TI) plasmablasts, as well as long-term follicular helper T cell-dependent (TD) IgM+ and switched memory cells (i.e., T-bet+ ABCs), and later discoveries of their role(s) in diverse immunological responses. These studies highlight a critical, although limited, role of T-bet in IgG2a class switching, a function central to the cells' role in immunity and autoimmunity. Given their association with autoimmunity, pharmacological targeting is an attractive strategy for reducing or eliminating the B cells. T-bet+ ABCs express a number of characteristic cell surface markers, including CD11c, CD11b, CD73, and the adenosine 2a receptor (A2aR). Accordingly, A2aR agonist administration effectively targeted T-bet+ ABCs in vivo. Moreover, agonist treatment of lupus-prone mice reduced autoantibodies and disease symptoms. This latter work highlights the potential therapeutic use of adenosine agonists for treating autoimmune diseases involving T-bet+ ABCs.
Keywords: ABCs; CD11c; T‐bet B cells; adenosine receptor; age‐associated B cells; ehrlichia.
© 2025 The Author(s). Immunological Reviews published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare the following competing interests: G.M.W. and R.C.L. are inventors listed on a patent pending for the use of A2A receptor agonists in the therapeutic depletion of CD11c + T‐bet+ B cells in diseases mediated by these B cells. Applicant: SUNY Research Foundation, Application Serial Number: PCT/US2019/045624.
Figures


Similar articles
-
Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus.Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18550-18560. doi: 10.1073/pnas.1901340116. Epub 2019 Aug 26. Proc Natl Acad Sci U S A. 2019. PMID: 31451659 Free PMC article.
-
Role of CD11c+ T-bet+ B cells in human health and disease.Cell Immunol. 2017 Nov;321:40-45. doi: 10.1016/j.cellimm.2017.05.008. Epub 2017 Jul 11. Cell Immunol. 2017. PMID: 28756897 Review.
-
T-bet+CD11c+ age-associated B cells resist BLyS- and CD20-targeted ablation in murine lupus models.J Autoimmun. 2025 May;153:103410. doi: 10.1016/j.jaut.2025.103410. Epub 2025 Mar 30. J Autoimmun. 2025. PMID: 40163938
-
Amelioration of Autoimmunity in a Lupus Mouse Model by Modulation of T-Bet-Promoted Energy Metabolism in Pathogenic Age/Autoimmune-Associated B Cells.Arthritis Rheumatol. 2023 Jul;75(7):1203-1215. doi: 10.1002/art.42433. Epub 2023 May 17. Arthritis Rheumatol. 2023. PMID: 36575806
-
T-bet+ memory B cells: Generation, function, and fate.Immunol Rev. 2019 Mar;288(1):149-160. doi: 10.1111/imr.12736. Immunol Rev. 2019. PMID: 30874358 Free PMC article. Review.
Cited by
-
Multifaceted, unique role of CD11c in leukocyte biology.Front Immunol. 2025 Mar 4;16:1556992. doi: 10.3389/fimmu.2025.1556992. eCollection 2025. Front Immunol. 2025. PMID: 40103815 Free PMC article. Review.
-
Plasma testosterone concentration is correlated with circulating immune cell abundance in transgender young people on gender-affirming hormone treatment.Front Immunol. 2025 Jul 10;16:1608543. doi: 10.3389/fimmu.2025.1608543. eCollection 2025. Front Immunol. 2025. PMID: 40709195 Free PMC article.
References
-
- Racine R., Chatterjee M., and Winslow G. M., “CD11c Expression Identifies a Population of Extrafollicular Antigen‐Specific Splenic Plasmablasts Responsible for CD4 T‐Independent Antibody Responses During Intracellular Bacterial Infection,” Journal of Immunology 181, no. 2 (2008): 1375–1385. - PMC - PubMed
-
- Matutes E., Martinez‐Trillos A., and Campo E., “Hairy Cell Leukaemia‐Variant: Disease Features and Treatment,” Best Practice & Research Clinical Haematology 28, no. 4 (2015): 253–263. - PubMed
-
- Szabo S. J., Kim S. T., Costa G. L., Zhang X., Fathman C. G., and Glimcher L. H., “A Novel Transcription Factor, T‐Bet, Directs Th1 Lineage Commitment,” Cell 100, no. 6 (2000): 655–669. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials